

# FDA Grants Approval for ReGenMed's 'Fountain of Youth Molecule' InfiNADi NAD+

BANGKOK, THAILAND, December 7, 2021 /EINPresswire.com/ -- Driven by innovation in the pursuit of excellence, ReGenMed proudly invites you to open your mind to a world of possibilities that exceed the paradigm of conventional medicine.

"Our company has been providing biomedicines to the region for over 15 years and is very excited about regulatory approvals in this field. It gives both access to our partners and medical providers, as well as a level of trust with the medical field that supports strong patient care options for our InfiNADi NAD+ offering." – Brian Dardzinski, M.Sc., Director

FDA Approved Innovation



ReGenMed is delighted to announce that their "InfiNADi NAD+ Anti-Aging Solution" is the first FDA-approved NAD+ in Southeast Asia. This product was approved by the Thailand FDA in October 2021. Initially launched in 2019, InfiNADi NAD+ is the #1 selling and most trusted NAD+ in Asia.

“

We are proud to be the first FDA approved NAD+ product in Asia.”

*Narin Apichairuk, President*

“We are proud to be the first FDA approved NAD+ product in Asia. The approval further confirms the quality and safety of our InfiNADi NAD+ product which now can be prescribed with an even higher level of confidence by our partner medical practitioners and hospitals.” - Narin Apichairuk, President

Thanks to popular research by renowned Dr. David Sinclair of Harvard University, we know that enhancing levels of the coenzyme, nicotinamide adenine dinucleotide, also known as NAD+, can help reverse signs of aging. This critical co-enzyme, referred to as “The Fountain of Youth Molecule,” is found in every cell of the body and is involved in hundreds of metabolic processes. NAD+ has two general sets of reactions in the human body: helping turn nutrients into energy as a key player in metabolism and working as a helper molecule for proteins that regulate other cellular functions. These processes are incredibly important, unfortunately, NAD+ levels decline by over 50% by the age of 40, hence the need to increase NAD+ levels to maintain optimal bodily functions.

## Their Vision and Ethos

NAD+ therapy is rapidly gaining momentum in both the anti-aging and medical space. ReGenMed maintains their market leader position as a trusted partner to support and nurture these pioneering advancements that medical practitioners can use to implement treatments within the upcoming field of regenerative medicine. This is the sole focus of the company for the past 15 years.

As they remain committed to being innovative leaders in the field of anti-aging and regenerative medicine, the company looks forward to launching more advanced products in Q4 of 2021 and through all of 2022. ReGenMed’s long-term vision inspires their expansive product developments that they look to introduce to the region and beyond.

## ABOUT Regenerative Medicine Co., Ltd.

Inspired by cutting-edge innovation, Regenerative Medicine Co., Ltd. (ReGenMed) are the leading biomedicine experts of advanced integrative, anti-aging and regenerative healthcare products. Focused on the South East Asia region, the company strives to make the inaccessible, accessible to medical practitioners around Asia. The company manufacture and distributes advanced biomedicine solutions. InfiNADi NAD+ is the first pharmaceutical grade, FDA-approved NAD+ launched in SE Asia.

## Website

[www.regenmedasia.com](http://www.regenmedasia.com)

Emmie Noe

Regenerative Medicine Co., Ltd.

+66 92 265 5660

emmie.noe@regenmedasia.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/557421611>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.